This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Jenrin Discovery, Inc
Drug Names(s): JD-5037
Description: JD-5037 is a peripherally selective (PS) inverse agonist of the CB1 receptor designed to minimize blood-brain barrier penetration and brain receptor interaction mediating the chief neuropsychiatric liability associated with first-generation brain penetrant CB1 receptor blockers.
Additional information available to subscribers only: